Amgen

For July through September, Amgen reported revenue up 8% to about $10.4 billion, beating analysts' expectations. Adjusted earnings per share rose to $6.45 versus $5.79 expected. The company raised its full-year guidance to revenue of $38.9–39.7 billion and adjusted EPS of $22.90–23.70. After the results, the stock climbed nearly 7% in premarket trading and topped the Dow. » More on deraktionaer.de

In the phase 3 trial CROSSING, Tezspire from Amgen (in collaboration with AstraZeneca) met both primary and key secondary endpoints in patients with eosinophilic esophagitis. After 24 weeks, histological remission rates were 64.8% (210 mg) and 68.9% (420 mg) versus 3.5% for placebo; the effect persisted at 52 weeks. Adverse events were mainly respiratory infections, headache and diarrhea; Amgen and AstraZeneca now plan to discuss the data with regulators to make the drug available quickly. » More on deraktionaer.de

Amgen yields about 2.6% versus Merck's 2.29% and has delivered consistent ~6% annual dividend increases compared with Merck's smaller mid-single-digit hikes. Amgen reports broader revenue diversification with 17 products at >$1bn, $3.5bn quarterly free cash flow and raised 2026 EPS guidance, supporting dividend coverage despite higher leverage. Merck relies heavily on Keytruda, faces peak-penetration risks and absorbed a $5.7bn acquisition charge that pushed Q2 GAAP results to a loss, leaving its dividend growth profile less certain. » More on finance.yahoo.com

Amgen fell about 5% after Novartis reported that pelacarsen substantially lowered Lp(a) but failed to reduce major cardiovascular events, challenging the hypothesis that Lp(a) lowering cuts clinical outcomes. Olpasiran, Amgen’s siRNA, achieves deeper Lp(a) reductions in earlier trials (>95% vs ~80%) but the Novartis miss lowers its probability of success rather than disproving it. Amgen’s diversified portfolio and other late‑stage assets cushion the impact, while olpasiran’s own outcomes will determine its ultimate valuation effect. » More on finance.yahoo.com

A late‑stage trial found that Amgen's Imdelltra combined with Imfinzi improved overall survival, progression‑free survival and response rates versus Imfinzi alone as maintenance therapy in patients with extensive‑stage small‑cell lung cancer, with no new safety signals. The result could expand Imdelltra's commercial role—it posted $513 million in sales last year—and strengthen Amgen's oncology franchise, though meaningful revenue gains depend on uptake in the maintenance setting. The data also supports AstraZeneca's Imfinzi franchise amid recent pipeline setbacks, but analysts caution the finding is constructive for long‑term oncology positioning rather than an immediate earnings transformation. » More on finance.yahoo.com